scholarly journals Replication Study: Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia

eLife ◽  
2017 ◽  
Vol 6 ◽  
Author(s):  
Xiaochuan Shan ◽  
Juan Jose Fung ◽  
Alan Kosaka ◽  
Gwenn Danet-Desnoyers ◽  
Keyword(s):  
Growth Inhibition ◽  
Effective Treatment ◽  
Cell Line ◽  
Cancer Biology ◽  
Vehicle Control ◽  
Original Study ◽  
Selective Growth ◽  
Significant Difference ◽  
K 562 Cells ◽  
Meta Analyses

In 2015, as part of the Reproducibility Project: Cancer Biology, we published a Registered Report (Fung et al., 2015), that described how we intended to replicate selected experiments from the paper "Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia" (Dawson et al., 2011). Here, we report the results of those experiments. We found treatment of MLL-fusion leukaemia cells (MV4;11 cell line) with the BET bromodomain inhibitor I-BET151 resulted in selective growth inhibition, whereas treatment of leukaemia cells harboring a different oncogenic driver (K-562 cell line) did not result in selective growth inhibition; this is similar to the findings reported in the original study (Figure 2A and Supplementary Figure 11A,B; Dawson et al., 2011). Further, I-BET151 resulted in a statistically significant decrease in BCL2 expression in MV4;11 cells, but not in K-562 cells; again this is similar to the findings reported in the original study (Figure 3D; Dawson et al., 2011). We did not find a statistically significant difference in survival when testing I-BET151 efficacy in a disseminated xenograft MLL mouse model, whereas the original study reported increased survival in I-BET151 treated mice compared to vehicle control (Figure 4B,D; Dawson et al., 2011). Differences between the original study and this replication attempt, such as different conditioning regimens and I-BET151 doses, are factors that might have influenced the outcome. We also found I-BET151 treatment resulted in a lower median disease burden compared to vehicle control in all tissues analyzed, similar to the example reported in the original study (Supplementary Figure 16A; Dawson et al., 2011). Finally, we report meta-analyses for each result.

scholarly journals Replication Study: Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs

eLife ◽  
2017 ◽  
Vol 6 ◽  
Author(s):  
Christine Mantis ◽  
Irawati Kandela ◽  
Fraser Aird ◽  
Keyword(s):  
Cancer Biology ◽  
Xenograft Model ◽  
Original Study ◽  
Cancer Drug ◽  
Tunel Staining ◽  
Positive Staining ◽  
Cancer Drugs ◽  
Tumor Weight ◽  
Significant Difference ◽  
Meta Analyses

In 2015, as part of the Reproducibility Project: Cancer Biology, we published a Registered Report (Kandela et al., 2015) that described how we intended to replicate selected experiments from the paper “Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs“ (Sugahara et al., 2010). Here we report the results of those experiments. We found that coadministration with iRGD peptide did not have an impact on permeability of the chemotherapeutic agent doxorubicin (DOX) in a xenograft model of prostate cancer, whereas the original study reported that it increased the penetrance of this cancer drug (Figure 2B; Sugahara et al., 2010). Further, in mice bearing orthotopic 22Rv1 human prostate tumors, we did not find a statistically significant difference in tumor weight for mice treated with DOX and iRGD compared to DOX alone, whereas the original study reported a decrease in tumor weight when DOX was coadministered with iRGD (Figure 2C; Sugahara et al., 2010). In addition, we did not find a statistically significant difference in TUNEL staining in tumor tissue between mice treated with DOX and iRGD compared to DOX alone, while the original study reported an increase in TUNEL positive staining with iRGD coadministration (Figure 2D; Sugahara et al., 2010). Similar to the original study (Supplemental Figure 9A; Sugahara et al., 2010), we did not observe an impact on mouse body weight with DOX and iRGD treatment. Finally, we report meta-analyses for each result.

scholarly journals Replication Study: Melanoma genome sequencing reveals frequent PREX2 mutations

eLife ◽  
2017 ◽  
Vol 6 ◽  
Author(s):  
Stephen K Horrigan ◽  
Pascal Courville ◽  
Darryl Sampey ◽  
Faren Zhou ◽  
Steve Cai ◽  
...  
Keyword(s):  
Genome Sequencing ◽  
Cancer Biology ◽  
Tumor Formation ◽  
Original Study ◽  
Free Survival ◽  
Tumor Onset ◽  
Study Evaluation ◽  
Significant Difference ◽  
Meta Analyses

In 2015, as part of the Reproducibility Project: Cancer Biology, we published a Registered Report (Chroscinski et al., 2014) that described how we intended to replicate selected experiments from the paper "Melanoma genome sequencing reveals frequent PREX2 mutations" (Berger et al., 2012). Here we report the results of those experiments. We regenerated cells stably expressing ectopic wild-type and mutant phosphatidylinositol-3,4,5-trisphosphate-dependent Rac exchange factor 2 (PREX2) using the same immortalized human NRASG12D melanocytes as the original study. Evaluation of PREX2 expression in these newly generated stable cells revealed varying levels of expression among the PREX2 isoforms, which was also observed in the stable cells made in the original study (Figure S6A; Berger et al., 2012). Additionally, ectopically expressed PREX2 was found to be at least 5 times above endogenous PREX2 expression. The monitoring of tumor formation of these stable cells in vivo resulted in no statistically significant difference in tumor-free survival driven by PREX2 variants, whereas the original study reported that these PREX2 mutations increased the rate of tumor incidence compared to controls (Figure 3B and S6B; Berger et al., 2012). Surprisingly, the median tumor-free survival was 1 week in this replication attempt, while 70% of the control mice were reported to be tumor-free after 9 weeks in the original study. The rapid tumor onset observed in this replication attempt, compared to the original study, makes the detection of accelerated tumor growth in PREX2 expressing NRASG12D melanocytes extremely difficult. Finally, we report meta-analyses for each result.

scholarly journals Replication Study: BET bromodomain inhibition as a therapeutic strategy to target c-Myc

eLife ◽  
2017 ◽  
Vol 6 ◽  
Author(s):  
Fraser Aird ◽  
Irawati Kandela ◽  
Christine Mantis ◽  
Keyword(s):  
Overall Survival ◽  
Cancer Biology ◽  
Therapeutic Strategy ◽  
Early Death ◽  
Vehicle Control ◽  
Tumor Burden ◽  
Original Study ◽  
Control Group ◽  
Minimal Impact ◽  
Significant Difference

In 2015, as part of the Reproducibility Project: Cancer Biology, we published a Registered Report (Kandela et al., 2015) that described how we intended to replicate selected experiments from the paper "BET bromodomain inhibition as a therapeutic strategy to target c-Myc" (Delmore et al., 2011). Here we report the results of those experiments. We found that treatment of human multiple myeloma (MM) cells with the small-molecular inhibitor of BET bromodomains, (+)-JQ1, selectively downregulated MYC transcription, which is similar to what was reported in the original study (Figure 3B; Delmore et al., 2011). Efficacy of (+)-JQ1 was evaluated in an orthotopically xenografted model of MM. Overall survival was increased in (+)-JQ1 treated mice compared to vehicle control, similar to the original study (Figure 7E; Delmore et al., 2011). Tumor burden, as determined by bioluminescence, was decreased in (+)-JQ1 treated mice compared to vehicle control; however, while the effect was in the same direction as the original study (Figure 7C-D; Delmore et al., 2011), it was not statistically significant. The opportunity to detect a statistically significant difference was limited though, due to the higher rate of early death in the control group, and increased overall survival in (+)-JQ1 treated mice before the pre-specified tumor burden analysis endpoint. Additionally, we evaluated the (−)-JQ1 enantiomer that is structurally incapable of inhibiting BET bromodomains, which resulted in a minimal impact on MYC transcription, but did not result in a statistically significant difference in tumor burden or survival distributions compared to treatment with (+)-JQ1. Finally, we report meta-analyses for each result.

scholarly journals Replication Study: Transcriptional amplification in tumor cells with elevated c-Myc

eLife ◽  
2018 ◽  
Vol 7 ◽  
Author(s):  
L Michelle Lewis ◽  
Meredith C Edwards ◽  
Zachary R Meyers ◽  
C Conover Talbot ◽  
Haiping Hao ◽  
...  
Keyword(s):  
Gene Expression ◽  
Tumor Cells ◽  
Cancer Biology ◽  
Statistical Significance ◽  
Digital Gene Expression ◽  
Original Study ◽  
Silent Genes ◽  
Before And After ◽  
Meta Analyses ◽  
Transcriptional Amplification

As part of the Reproducibility Project: Cancer Biology, we published a Registered Report (Blum et al., 2015), that described how we intended to replicate selected experiments from the paper ‘Transcriptional amplification in tumor cells with elevated c-Myc’ (Lin et al., 2012). Here we report the results. We found overexpression of c-Myc increased total levels of RNA in P493-6 Burkitt’s lymphoma cells; however, while the effect was in the same direction as the original study (Figure 3E; Lin et al., 2012), statistical significance and the size of the effect varied between the original study and the two different lots of serum tested in this replication. Digital gene expression analysis for a set of genes was also performed on P493-6 cells before and after c-Myc overexpression. Transcripts from genes that were active before c-Myc induction increased in expression following c-Myc overexpression, similar to the original study (Figure 3F; Lin et al., 2012). Transcripts from genes that were silent before c-Myc induction also increased in expression following c-Myc overexpression, while the original study concluded elevated c-Myc had no effect on silent genes (Figure 3F; Lin et al., 2012). Treating the data as paired, we found a statistically significant increase in gene expression for both active and silent genes upon c-Myc induction, with the change in gene expression greater for active genes compared to silent genes. Finally, we report meta-analyses for each result.

scholarly journals Cytotoxic Effect of Gliotoxin, Hemolysin, Protease and Melanin purified from Aspergillus fumigates on REF Cell Line, in vitro Study

2015 ◽  
Vol 9 (2) ◽  
pp. 4-10
Author(s):  
Batool Omran Theeb Theeb ◽  
Farooq Ibrahem Mohammad Mohammad ◽  
Abdulkareem Jasim Hashim Hashim
Keyword(s):  
Growth Inhibition ◽  
Cell Line ◽  
Cytotoxic Effect ◽  
In Vitro Study ◽  
Toxic Substances ◽  
Aspergillus Fumigates ◽  
Significant Difference ◽  
Embryonic Fibroblast ◽  
Compound Concentration

Aspergillus fumigates especially clinical isolate produces a series of toxic substances and proteinaceous hemolysin, protease and pigment like melanin which appear to act in an additive and synergic way on cells. In this study, gliotoxin, hemolysin, Protease, and Melanin were used in an experimental model to study their Cytotoxic activity by evaluating their effect on REF cell line (Rat embryonic fibroblast ), for exposure time of 24 hrs at three different concentrations of each compounds triplicate of each concentration were used, cytotoxicity of the purified compounds were active against REF cell line under study and a toxic effect was clear with a significant difference at the level of probability (p≤ 0.05) and this effect was contrasted among different concentrations for each purified compound growth inhibition of REF cell line was increase gradually with the increase of compound concentration.

scholarly journals Replication Study: A coding-independent function of gene and pseudogene mRNAs regulates tumour biology

eLife ◽  
2020 ◽  
Vol 9 ◽  
Author(s):  
John Kerwin ◽  
Israr Khan ◽  
Elizabeth Iorns ◽  
Rachel Tsui ◽  
Alexandria Denis ◽  
...  
Keyword(s):  
Cancer Biology ◽  
Cancer Cell Line ◽  
Prostate Cancer Cell Line ◽  
Original Study ◽  
Mrna Levels ◽  
Independent Function ◽  
Tumour Biology ◽  
Pten Mrna ◽  
Du145 Cells ◽  
Meta Analyses

As part of the Reproducibility Project: Cancer Biology we published a Registered Report (Khan et al., 2015), that described how we intended to replicate selected experiments from the paper "A coding-independent function of gene and pseudogene mRNAs regulates tumour biology" (Poliseno et al., 2010). Here we report the results. We found PTEN depletion in the prostate cancer cell line DU145 did not detectably impact expression of the corresponding pseudogene PTENP1. Similarly, depletion of PTENP1 did not impact PTEN mRNA levels. The original study reported PTEN or PTENP1 depletion statistically reduced the corresponding pseudogene or gene (Figure 2G; Poliseno et al., 2010). PTEN and/or PTENP1 depletion in DU145 cells decreased PTEN protein expression, which was similar to the original study (Figure 2H; Poliseno et al., 2010). Further, depletion of PTEN and/or PTENP1 increased DU145 proliferation compared to non-targeting siRNA, which was in the same direction as the original study (Figure 2F; Poliseno et al., 2010), but not statistically significant. We found PTEN 3'UTR overexpression in DU145 cells did not impact PTENP1 expression, while the original study reported PTEN 3'UTR increased PTENP1 levels (Figure 4A; Poliseno et al., 2010). Overexpression of PTEN 3'UTR also statistically decreased DU145 proliferation compared to controls, which was similar to the findings reported in the original study (Figure 4A; Poliseno et al., 2010). Differences between the original study and this replication attempt, such as level of knockdown efficiency and cellular confluence, are factors that might have influenced the results. Finally, where possible, we report meta-analyses for each result.

scholarly journals Replication Study: Wnt activity defines colon cancer stem cells and is regulated by the microenvironment

eLife ◽  
2019 ◽  
Vol 8 ◽  
Author(s):  
Anthony Essex ◽  
Javier Pineda ◽  
Grishma Acharya ◽  
Hong Xin ◽  
James Evans ◽  
...  
Keyword(s):  
Stem Cells ◽  
Colon Cancer ◽  
Cancer Stem Cells ◽  
Cancer Biology ◽  
Statistical Significance ◽  
Original Study ◽  
Secreted Factors ◽  
Colon Cancer Stem Cells ◽  
Meta Analyses

As part of the Reproducibility Project: Cancer Biology we published a Registered Report (Evans et al., 2015), that described how we intended to replicate selected experiments from the paper ‘Wnt activity defines colon cancer stem cells and is regulated by the microenvironment’ (Vermeulen et al., 2010). Here, we report the results. Using three independent primary spheroidal colon cancer cultures that expressed a Wnt reporter construct we observed high Wnt activity was associated with the cell surface markers CD133, CD166, and CD29, but not CD24 and CD44, while the original study found all five markers were correlated with high Wnt activity (Figure 2F; Vermeulen et al., 2010). Clonogenicity was highest in cells with high Wnt activity and clonogenic potential of cells with low Wnt activity were increased by myofibroblast-secreted factors, including HGF. While the effects were in the same direction as the original study (Figure 6D; Vermeulen et al., 2010) whether statistical significance was reached among the different conditions varied. When tested in vivo, we did not find a difference in tumorigenicity between high and low Wnt activity, while the original study found cells with high Wnt activity were more effective in inducing tumors (Figure 7E; Vermeulen et al., 2010). Tumorigenicity, however, was increased with myofibroblast-secreted factors, which was in the same direction as the original study (Figure 7E; Vermeulen et al., 2010), but not statistically significant. Finally, we report meta-analyses for each results where possible.

scholarly journals Replication Study: The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44

eLife ◽  
2019 ◽  
Vol 8 ◽  
Author(s):  
Xuefei Yan ◽  
Beibei Tang ◽  
Biao Chen ◽  
Yongli Shan ◽  
Huajun Yang ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Stem Cells ◽  
Cancer Stem Cells ◽  
Binding Sites ◽  
Cancer Biology ◽  
Original Study ◽  
Cd44 Expression ◽  
Prostate Cancer Stem Cells ◽  
Significant Difference

As part of the Reproducibility Project: Cancer Biology, we published a Registered Report (Li et al., 2015), that described how we intended to replicate selected experiments from the paper ‘The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44’ (Liu et al., 2011). Here we report the results. We found the microRNA, miR-34a, was expressed at twice the level in CD44+ prostate cancer cells purified from xenograft tumors (LAPC4 cells) compared to CD44- LAPC4 cells, whereas the original study reported miR-34a was underexpressed in CD44+ LAPC4 cells (Figure 1B; Liu et al., 2011). When LAPC4 cells engineered to express miR-34a were injected into mice, we did not observe changes in tumor growth or CD44 expression; however, unexpectedly miR-34a expression was lost in vivo. In the original study, LAPC4 cells expressing miR-34a had a statistically significant reduction in tumor regeneration and reduced CD44 expression compared to control (Figure 4A and Supplemental Figures 4A,B and 5C; Liu et al., 2011). Furthermore, when we tested if miR-34a regulated CD44 through binding sites in the 3’UTR we did not find a statistically significant difference, whereas the original study reported miR-34a decreased CD44 expression that was partially abrogated by mutation of the binding sites in the CD44 3’UTR (Figure 4D; Liu et al., 2011). Finally, where possible, we report meta-analyses for each result.

scholarly journals Endocrine therapy-based treatments in hormone receptor-positive/HER2-negative advanced breast cancer: systematic review and network meta-analysis

ESMO Open ◽  
2020 ◽  
Vol 5 (4) ◽  
pp. e000842
Author(s):  
Mariana Brandão ◽  
Christian Maurer ◽  
Patricia Klarmann Ziegelmann ◽  
Noam F Pondé ◽  
Arlindo Ferreira ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Advanced Breast Cancer ◽  
Effective Treatment ◽  
Endocrine Therapy ◽  
Hormone Receptor ◽  
Advanced Breast ◽  
Hormone Receptor Positive ◽  
Significant Difference ◽  
Meta Analyses

BackgroundSeveral endocrine therapy (ET)-based treatments are available for patients with advanced breast cancer. We assessed the efficacy of different ET-based treatments in patients with hormone receptor-positive/HER2-negative advanced breast cancer with endocrine-sensitive or endocrine-resistant disease.MethodsWe searched Medline and Cochrane Central Register of Controlled Trials up to 15 October 2019 and abstracts from major conferences from 2016 to October 2019. We included phase II/III randomised trials, comparing ≥2 ET-based treatments. Progression-free survival (PFS) and overall survival (OS) were analysed by network meta-analyses using MTC Bayesian models based on both fixed-effect and random-effect models; relative treatment effects were measured as HRs and 95% credibility intervals (CrI). All statistical tests were two-sided. Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were followed and this systematic review is registered in the PROSPERO database.Results55 publications reporting on 32 trials (n=12 293 patients) were included. Regarding PFS in the endocrine sensitive setting (n=5200; 12 trials), the combination of cyclin-dependent kinases (CDK)4/6-inhibitors (CDK4/6i)+fulvestrant 500 mg (F500) was likely the most effective treatment (surface under the cumulative ranking curve (SUCRA)=97.3%), followed by CDK4/6i+aromatase inhibitor ±goserelin; there was no significant difference between them (HR 0.82; 95% CrI 0.54–1.25). Regarding OS (n=2157; five trials), the most effective treatment was probably CDK4/6i+F500 (SUCRA=97.3%); comparing CDK4/6i+F500 versus F500 held a HR of 0.77 (95% CrI 0.63–0.95). Regarding PFS in the endocrine-resistant setting (n=6635; 20 trials), CDK4/6i+F500 was likely the most effective treatment (SUCRA=95.7%), followed by capivasertib+F500, without significant difference between them (HR 0.91; 95% CrI 0.60–1.36). For OS (n=4377; 11 trials), the most effective treatments were capivasertib+F500 (SUCRA=84.7%) and CDK4/6i+F500 (SUCRA=69.9%). Comparing CDK4/6i+F500 versus F500 held a HR of 0.77 (95% CrI 0.67–0.89).ConclusionsCDK4/6i+F500 is likely the best treatment option in both endocrine-sensitive and endocrine-resistant diseases for PFS, and in endocrine-sensitive patients for OS. Concerning OS in endocrine-resistant patients, capivasertib+F500 and CDK4/6i+F500 are likely the best treatments.PROSPERO registration numberCRD42018104628.

Sign in / Sign up

Export Citation Format

Share Document